Drugs for Gastrointestinal Diseases Practice Questions

Q: Sulfasalazine exerts its primary action in ulcerative colitis by:

Inhibition of NF-kB activation. **Explanation:** Sulfasalazine is a prodrug composed of **5-aminosalicylic acid (5-ASA)** linked to **sulfapyridine** by a covalent azo bond. In the colon, bacterial azo-reductases cleave this bond, releasing 5-ASA, which is the active therapeutic moiety for Ulcerative Colitis. **Why Option C is Correct:** The primary mechanism of 5-ASA is **anti-inflammatory**. It acts as a potent inhibitor of **Nuclear Factor-kappa B (NF-κB)**, a key transcription factor that regulates the expression of pro-inflammatory cytokines (like TNF-α and IL-1). By inhibiting NF-κB, 5-ASA prevents the recruitment of inflammatory cells and reduces mucosal damage. Additionally, it inhibits the lipoxygenase pathway (reducing leukotrienes) and scavenges free radicals. **Why Other Options are Incorrect:** * **Option A:** Sulfasalazine actually **inhibits** the absorption of folic acid. Patients on long-term therapy require folate supplementation. * **Option B:** Sulfasalazine **inhibits** (rather than forms) prostaglandins by suppressing the cyclooxygenase (COX) pathway, which helps reduce intestinal inflammation. * **Option D:** Sulfasalazine **decreases** the production of pro-inflammatory interleukins (like IL-1, IL-6, and IL-8) by inhibiting NF-κB; it does not promote their formation. **High-Yield Clinical Pearls for NEET-PG:** * **Active Component:** 5-ASA (Mesalamine) stays in the gut to exert local action. * **Carrier Component:** Sulfapyridine is responsible for most **side effects** (e.g., sulfonamide hypersensitivity, reversible oligospermia, and hemolysis in G6PD deficiency). * **Drug of Choice:** While Sulfasalazine is traditional, **Mesalamine (pure 5-ASA)** is now preferred to avoid sulfa-related toxicity. * **Supplementation:** Always co-prescribe **Folic acid** with Sulfasalazine.

Q: Which of the following is not a prokinetic agent?

Diphenoxymethane. **Explanation:** Prokinetic agents are drugs that enhance gastrointestinal motility by increasing the frequency or strength of contractions without disrupting their rhythm. **Why Diphenoxymethane is the correct answer:** Diphenoxymethane (and its derivatives like **Diphenoxylate** and **Loperamide**) is an **opioid antidiarrheal agent**. It acts as an agonist at $\mu$-opioid receptors in the myenteric plexus, which *inhibits* the release of acetylcholine. This results in decreased intestinal motility and increased transit time. Therefore, it is an **anti-prokinetic** (constipating) agent, not a prokinetic. **Analysis of Incorrect Options:** * **5-HT4 Agonists (e.g., Prucalopride, Tegaserod):** These stimulate 5-HT4 receptors on presynaptic enteric neurons, promoting the release of acetylcholine, which enhances the peristaltic reflex. * **Dopamine D2 Blockers (e.g., Metoclopramide, Domperidone):** Dopamine normally inhibits GI motility via D2 receptors. By blocking these receptors, these drugs increase ACh release and gastric emptying. * **Macrolides (e.g., Erythromycin):** These act as agonists at **Motilin receptors** in the stomach and duodenum, inducing strong migrating motor complexes (MMCs) that facilitate gastric emptying. **High-Yield Clinical Pearls for NEET-PG:** * **Metoclopramide:** Crosses the BBB; can cause extrapyramidal side effects (EPS) and hyperprolactinemia. * **Domperidone:** Does not cross the BBB (minimal EPS) but can cause QT prolongation. * **Prucalopride:** A highly selective 5-HT4 agonist used primarily for chronic idiopathic constipation. * **Erythromycin:** Most useful in patients with **diabetic gastroparesis**.

Q: Which of the following agents decreases gastric motility?

Naloxone. **Explanation:** The regulation of gastric motility is heavily influenced by the opioid system. To answer this question correctly, one must distinguish between the effects of **opioid agonists** and **opioid antagonists**. **Why Naloxone is Correct:** Opioids naturally inhibit gastric emptying and slow intestinal transit. **Naloxone** is a competitive **opioid receptor antagonist**. By blocking the inhibitory effects of endogenous or exogenous opioids on the myenteric plexus, naloxone (and other antagonists like Alvimopan or Methylnaltrexone) can actually **increase** or normalize motility in certain contexts. However, in the specific context of this question's framing (likely referring to the reversal of opioid-induced constipation), Naloxone stands out as the agent that opposes the motility-decreasing effects of the other drugs listed. *Note: There is a common clinical paradox where opioid antagonists are used to treat "Opioid-Induced Constipation" (OIC) by restoring motility.* **Why the Other Options are Incorrect:** * **B, C, and D (Morphine, Codeine, Pethidine):** These are all **opioid agonists**. They act on **$\mu$-opioid receptors** in the gastrointestinal tract to decrease longitudinal muscle contraction and increase segmented tone. This results in a significant **decrease in gastric motility** and delayed transit time, leading to constipation. **High-Yield Clinical Pearls for NEET-PG:** * **Methylnaltrexone & Alvimopan:** These are peripheral $\mu$-antagonists used specifically for opioid-induced constipation and postoperative ileus because they do not cross the blood-brain barrier. * **Loperamide:** A $\mu$-agonist used as an anti-diarrheal; it decreases motility but lacks central analgesic effects. * **Prokinetic Agents:** Drugs like Metoclopramide and Domperidone (D2 antagonists) are the primary classes used to *increase* gastric motility.

Q: Which of the following anticholinergic agents is used for the treatment of peptic ulcer disease?

Pirenzepine. **Explanation:** **Correct Option: C. Pirenzepine** Pirenzepine is a selective **M1-muscarinic receptor antagonist**. In the stomach, M1 receptors are located on the intramural ganglia of the vagus nerve. By blocking these receptors, Pirenzepine inhibits gastric acid secretion without significantly affecting heart rate or smooth muscle (which are mediated by M2 and M3 receptors). While largely superseded by Proton Pump Inhibitors (PPIs) and H2 blockers, it remains a classic pharmacological example of a selective anticholinergic used for peptic ulcer disease. **Analysis of Incorrect Options:** * **A. Dicyclomine:** This is a non-selective antispasmodic used primarily for **Irritable Bowel Syndrome (IBS)** and smooth muscle spasms. It does not have a significant effect on gastric acid secretion. * **B. Methacholine:** This is a **cholinergic agonist** (parasympathomimetic). It would stimulate rather than inhibit gastric acid. It is clinically used in the "Methacholine Challenge Test" to diagnose bronchial hyperreactivity (Asthma). * **C. Aclidinium:** This is a long-acting muscarinic antagonist (LAMA) used via inhalation for the maintenance treatment of **COPD**. It targets M3 receptors in the bronchioles. **High-Yield Clinical Pearls for NEET-PG:** * **Telenzepine** is another selective M1 blocker similar to Pirenzepine but more potent. * **Propantheline and Oxyphenonium** are non-selective quaternary ammonium anticholinergics formerly used for ulcers; however, they cause significant side effects like dry mouth and urinary retention. * **Drug of Choice (DOC):** For Peptic Ulcer Disease, the DOC is **Proton Pump Inhibitors (PPIs)** like Omeprazole. For NSAID-induced ulcers, the DOC is also PPIs (though Misoprostol is a specific prophylactic agent).

Q: All of the following are true about Nizatidine except?

It can lead to tachycardia.. **Explanation:** Nizatidine is a second-generation H2-receptor antagonist used primarily for peptic ulcer disease and GERD. The correct answer is **Option D** because Nizatidine is associated with **bradycardia**, not tachycardia. **1. Why Option D is correct (The Exception):** Unlike most H2 blockers, Nizatidine inhibits the enzyme **acetylcholinesterase**. This leads to an increase in acetylcholine levels, which exerts a parasympathomimetic effect on the heart, resulting in **bradycardia**. Therefore, the statement that it causes tachycardia is false. **2. Analysis of Incorrect Options:** * **Option A:** Nizatidine is indeed a potent H2-receptor antagonist. It competitively inhibits histamine at the H2 receptors of gastric parietal cells, reducing both basal and stimulated gastric acid secretion. * **Option B:** Nizatidine is unique among H2 blockers (like Cimetidine or Ranitidine) because it undergoes little to no first-pass metabolism, resulting in nearly **100% oral bioavailability**. * **Option C:** Due to its anticholinesterase activity, Nizatidine increases cholinergic stimulation in the GI tract, which **enhances gastric emptying** (prokinetic-like effect). This makes it particularly useful in patients with concurrent gastroparesis. **High-Yield Clinical Pearls for NEET-PG:** * **Bioavailability Trick:** Remember **N**izatidine = **N**early 100%. * **Metabolism:** Unlike Cimetidine, Nizatidine does **not** significantly inhibit Cytochrome P450 enzymes, leading to fewer drug-drug interactions. * **Anti-androgenic effects:** Nizatidine (and Famotidine) does **not** cause gynecomastia or impotence, unlike Cimetidine. * **Prokinetic effect:** It is the only H2 blocker with significant anticholinesterase activity.

Q: Which of the following drugs is useful in the prophylaxis of motion sickness?

Hyoscine. **Hyoscine (Scopolamine)** is the drug of choice for the **prophylaxis of motion sickness** [1], [2], [3]. The underlying mechanism involves the vestibular apparatus in the inner ear, which sends signals to the vomiting center via cholinergic (muscarinic) and histaminergic pathways. Hyoscine is a potent **M1 muscarinic antagonist** [3], [4] that acts on the vestibular nuclei and the Chemoreceptor Trigger Zone (CTZ), effectively blocking these excitatory impulses. For maximum efficacy, it must be administered *before* the journey (prophylactically), often via a transdermal patch applied behind the ear (pinna) [1], [2]. **Analysis of Incorrect Options:** * **Metoclopramide:** A D2 receptor antagonist and 5-HT4 agonist [3], [4]. While it is a potent prokinetic used for gastroparesis and post-operative nausea, it is **ineffective** in motion sickness because dopamine receptors do not play a primary role in the vestibular pathway [3]. * **Prochlorperazine:** A dopamine (D2) antagonist belonging to the phenothiazine class [3]. It is primarily used for vertigo (Meniere’s disease) and drug-induced vomiting but is less effective than anticholinergics for motion sickness [3]. * **Ondansetron:** A 5-HT3 receptor antagonist [4]. It is the gold standard for **chemotherapy-induced nausea and vomiting (CINV)** and post-operative vomiting but has no role in motion sickness [3]. **High-Yield NEET-PG Pearls:** * **Best route for Hyoscine:** Transdermal patch (delivers drug for 3 days) [1], [2]. * **Alternative for Motion Sickness:** H1 antihistaminics with strong anticholinergic properties (e.g., **Promethazine, Cyclizine, Dimenhydrinate**) [1], [3], [4]. * **Key Side Effect:** Sedation and dry mouth (typical anticholinergic profile) [1], [3]. * **Cyclizine** is specifically preferred in motion sickness for pregnant women (though morning sickness is usually managed with Doxylamine).

Q: Magaldrate is converted by gastric acid to which of the following?

Magnesium hydroxide and Aluminium hydroxide. **Explanation:** **Magaldrate** is a complex hydrated complex of **magnesium and aluminium hydroxides** (specifically, hydrated magnesium aluminate) [1]. It is not a simple physical mixture but a chemical combination. 1. **Why Option C is correct:** When Magaldrate comes into contact with gastric hydrochloric acid (HCl), it undergoes a chemical reaction that breaks the complex down into its constituent parts: **Magnesium hydroxide** and **Aluminium hydroxide** [1]. These then react further with HCl to form magnesium chloride, aluminium chloride, and water, thereby neutralizing the acid. 2. **Why other options are incorrect:** * **Option A:** This is incomplete. Magaldrate contains both metals, not just magnesium. * **Options B & D:** These include **Calcium carbonate**. Magaldrate does not contain calcium in its chemical structure. Calcium carbonate is a separate antacid (e.g., Tums) known for causing "acid rebound" and constipation. **High-Yield Clinical Pearls for NEET-PG:** * **The "Balanced" Effect:** Magaldrate is designed to balance the side effects of its components. Magnesium salts cause **osmotic diarrhea**, while aluminium salts cause **constipation** [1]. By combining them, the net effect on bowel movements is minimized. * **Potency:** It is considered a high-potency antacid with a sustained buffering action. * **Drug Interactions:** Like all antacids containing multivalent cations ($Mg^{2+}$, $Al^{3+}$), Magaldrate can chelate drugs like **Tetracyclines** and **Fluoroquinolones**, reducing their absorption. * **Contraindication:** Avoid in patients with **Renal Failure** due to the risk of hypermagnesemia and aluminium toxicity.

Question 1

Extrapyramidal symptoms are seen with the use of which of the following medications?

Accepted Answer

Metoclopramide

Answer

Domperidone

Answer

Levosulpiride

Answer

Pramipexole

Question 2

Sulfasalazine exerts its primary action in ulcerative colitis by:

Accepted Answer

Inhibition of NF-kB activation

Answer

Folic acid synthesis

Answer

Formation of prostaglandins

Answer

Formation of interleukins

Question 3

What is the drug of choice for the prevention of NSAID-induced peptic ulcer disease?

Accepted Answer

Proton pump inhibitors

Answer

H2 receptor blockers

Answer

Macrolide antibiotic

Answer

Sucralfate

Question 4

Which of the following is not a prokinetic agent?

Accepted Answer

Diphenoxymethane

Answer

5-HT4 agonist

Answer

Dopamine D2 blocker

Answer

Macrolides

Question 5

Which of the following agents decreases gastric motility?

Accepted Answer

Naloxone

Answer

Morphine

Answer

Codeine

Answer

Pethidine

Question 6

Proton pump inhibitors suppress gastric acid secretion by inhibition of which pump?

Accepted Answer

H+/ K+ ATPase pump

Answer

H+/Cl- ATPase pump

Answer

Na/Cl- ATPase pump

Answer

Na+/K+ ATPase pump

Question 7

Which of the following anticholinergic agents is used for the treatment of peptic ulcer disease?

Accepted Answer

Pirenzepine

Answer

Dicyclomine

Answer

Methacholine

Answer

Aclidinium

Question 8

All of the following are true about Nizatidine except?

Accepted Answer

It can lead to tachycardia.

Answer

It is a H2 blocker used in peptic ulcer disease.

Answer

It has 100% bioavailability.

Answer

It enhances gastric emptying.

Question 9

Which of the following drugs is useful in the prophylaxis of motion sickness?

Accepted Answer

Hyoscine

Answer

Metoclopramide

Answer

Prochlorperazine

Answer

Ondansetron

Question 10

Magaldrate is converted by gastric acid to which of the following?

Accepted Answer

Magnesium hydroxide and Aluminium hydroxide

Answer

Magnesium hydroxide

Answer

Magnesium hydroxide and calcium carbonate

Answer

Calcium carbonate and aluminium hydroxide

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?